<DOC>
	<DOC>NCT00054899</DOC>
	<brief_summary>EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Non-Small Cell Lung Cancer.</brief_summary>
	<brief_title>An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Confirmed diagnosis of NonSmall Cell Lung Cancer, stage IIb or IIIa At least four weeks following prior standard treatment, with no evidence of disease Must use adequate birth control Prior cancer vaccine therapy or concurrent participation in any other investigational study A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine Women who are pregnant, intend to become pregnant, or who are breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>vaccine</keyword>
	<keyword>lung</keyword>
	<keyword>cancer</keyword>
	<keyword>Carcinoma, Large Cell</keyword>
	<keyword>Non-Small-Cell Lung Carcinoma</keyword>
</DOC>